Pfizer: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Pfizer as lead sponsor. 1 are open to participants now and 9 have results posted.
Phase 2 3Phase 3 1Phase 4 2No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 2
- BESPONSA Injection 1 mg Special InvestigationCompletedNCT05923112Results posted
- A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT05687032Phase 4Results posted
- A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last TreatmentCompletedNCT05597085Results posted
- Latin American Real-world Study in Acute LeukemiaCompletedNCT05166135Results posted
- InO - A Retrospective Study of UK Patients With LeukaemiaCompletedNCT04456959Results posted
- A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsCompletedNCT03677596Phase 4Results posted
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic LeukemiaCompletedNCT01564784Phase 3Results posted
- Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
- Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic LeukemiaCompletedNCT01363297Phase 2Results posted
- A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.Active, not recruitingNCT06476665